Early Identification of Adverse Events Coaching Guide

This resource has been developed to support HCPs with their clinical screening and early identification of adverse events (AEs) when treating patients with KEYTRUDA (pembrolizumab) + enfortumab vedotin▼ (EV). This guide provides information on the potential risk factors, signs, and symptoms of seven AEs of clinical interest for KEYTRUDA + EV. It also includes screening questions for HCPs to use during patient consultations to support early detection of treatment-related AEs.

Please note, this resource is for digital use only and is not intended to be printed. If you would like to request the printed version of this resource please email msdukoncology@msd.com.

Prescribing Information [External link]

Early Identification of Adverse Events Coaching Guide

KEYTRUDA, in combination with enfortumab vedotin, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults.1

Please refer to the Summary of Product Characteristics and Risk Minimisation Materials for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.

Abbreviations

HCPs; Healthcare Professionals

Reference

  1. KEYTRUDA Summary of Product Characteristics.
GB-PDO-03714 | Date of Preparation: October 2025